Nurix Therapeutics (NRIX) Stock Forecast & Price Target

Compare

430 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NRIX Analyst Ratings

Strong Buy

13 Buy

2 Hold

0 Sell

Based on 15 analysts giving stock ratings to

Nurix

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NRIX Stock 12 Month Forecast

Average Price Target

$29.50

▲(153.44%Upside)

Based on 15 Wall Street analysts offering 12 month price targets for Nurix Therapeutics in the last 3 months. The average price target is $29.50 with a high forecast of $36.00 and a low forecast of $16.00. The average price target represents a 153.44% change from the last price of $11.64.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"$9","16":"$16","23":"$23","30":"$30","37":"$37"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":36,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$36.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":29.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$29.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$16.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,16,23,30,37],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.14,13.975384615384616,15.810769230769232,17.646153846153847,19.481538461538463,21.316923076923075,23.152307692307694,24.987692307692306,26.823076923076925,28.658461538461538,30.493846153846153,32.32923076923077,34.16461538461539,{"y":36,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.14,13.475384615384616,14.810769230769232,16.146153846153847,17.481538461538463,18.81692307692308,20.152307692307694,21.487692307692306,22.823076923076925,24.158461538461538,25.493846153846157,26.82923076923077,28.164615384615384,{"y":29.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.14,12.436923076923078,12.733846153846155,13.03076923076923,13.327692307692308,13.624615384615385,13.921538461538463,14.21846153846154,14.515384615384615,14.812307692307693,15.10923076923077,15.406153846153845,15.703076923076924,{"y":16,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.75,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.91,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.47,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.2,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.09,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.47,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.49,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.84,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.71,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.45,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.47,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.16,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.14,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$36.00

Average Price Target$29.50

Lowest Price Target$16.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$12

Hold

3.09%

Upside

Reiterated

06/28/25

The overall score reflects the strong impact of recent positive clinical trial results, which improve the outlook despite ongoing financial challenges. Technical indicators show balanced momentum, but valuation concerns persist due to unprofitability.

Matthew BieglerOppenheimer

Oppenheimer

$32

Buy

174.91%

Upside

Reiterated

06/27/25

Oppenheimer Remains a Buy on Nurix Therapeutics (NRIX)

Faisal KhurshidLeerink Partners

Leerink Partners

$16

Hold

37.46%

Upside

Reiterated

06/16/25

Analysts Conflicted on These Healthcare Names: Align Tech (NASDAQ: ALGN), Nurix Therapeutics (NASDAQ: NRIX) and Thermo Fisher (NYSE: TMO)

Jeet MukherjeeBTIG

BTIG

$35

Buy

200.69%

Upside

Reiterated

06/13/25

Promising Developments in Nurix Therapeutics' BTK Degrader Drive Buy Rating

Srikripa DevarakondaTruist Financial

Truist Financial

―

Buy

―

Reiterated

06/13/25

Truist Financial Keeps Their Buy Rating on Nurix Therapeutics (NRIX)

David DaiUBS

UBS

$30

Buy

157.73%

Upside

Reiterated

06/13/25

UBS reiterates Buy Rating on Nurix (NRIX)UBS analyst David Dai reiterated a Buy rating and $30.00 price target on Nurix (NASDAQ: NRIX).

Peter LawsonBarclays

Barclays

$31

Buy

166.32%

Upside

Reiterated

06/13/25

Barclays Remains a Buy on Nurix Therapeutics (NRIX)

Derek ArchilaWells Fargo

Wells Fargo

$25

Buy

114.78%

Upside

Reiterated

06/12/25

Analysts' Top Healthcare Picks: Nurix Therapeutics (NRIX), Disc Medicine (IRON)

Brian AbrahamsRBC Capital

RBC Capital

$28

Buy

140.55%

Upside

Reiterated

06/12/25

RBC Capital Sticks to Its Buy Rating for Nurix Therapeutics (NRIX)

Gil BlumNeedham

Needham

$27

Buy

131.96%

Upside

Reiterated

06/12/25

Analysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NASDAQ: NRIX) and Telix Pharmaceuticals (Other OTC: TLPPF)

Stephen WilleyStifel Nicolaus

Stifel Nicolaus

$36→$35

Buy

200.69%

Upside

Reiterated

06/02/25

Optimistic Outlook on Nurix Therapeutics: Strategic Partnerships and Financial Gains Drive Buy Rating

Biren AminPiper Sandler

Piper Sandler

$35

Buy

200.69%

Upside

Reiterated

05/07/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Terence FlynnMorgan Stanley

Morgan Stanley

$17

Hold

46.05%

Upside

Reiterated

04/10/25

Cautious Outlook on Nurix Therapeutics Amid Promising Pipeline and Development Uncertainties

Christopher LiuLucid Capital

Lucid Capital

$35→$36

Buy

209.28%

Upside

Reiterated

04/09/25

Nurix (NRIX) PT Raised to $36 at Lucid Capital MarketsLucid Capital Markets analyst Christopher Liu raised the price target on Nurix (NASDAQ: NRIX) to $36.00 (from $35.00) while maintaining a Buy rating.

Sudan LoganathanStephens

Stephens

$31→$30

Buy

157.73%

Upside

Reiterated

04/09/25

Nurix (NRIX) PT Lowered to $30 at StephensStephens analyst Sudan Loganathan lowered the price target on Nurix (NASDAQ: NRIX) to $30.00 (from $31.00) while maintaining a Overweight rating.

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$12

Hold

3.09%

Upside

Reiterated

06/28/25

Matthew BieglerOppenheimer

Oppenheimer

$32

Buy

174.91%

Upside

Reiterated

06/27/25

Oppenheimer Remains a Buy on Nurix Therapeutics (NRIX)

Faisal KhurshidLeerink Partners

Leerink Partners

$16

Hold

37.46%

Upside

Reiterated

06/16/25

Analysts Conflicted on These Healthcare Names: Align Tech (NASDAQ: ALGN), Nurix Therapeutics (NASDAQ: NRIX) and Thermo Fisher (NYSE: TMO)

Jeet MukherjeeBTIG

BTIG

$35

Buy

200.69%

Upside

Reiterated

06/13/25

Promising Developments in Nurix Therapeutics' BTK Degrader Drive Buy Rating

Srikripa DevarakondaTruist Financial

Truist Financial

―

Buy

―

Reiterated

06/13/25

Truist Financial Keeps Their Buy Rating on Nurix Therapeutics (NRIX)

David DaiUBS

UBS

$30

Buy

157.73%

Upside

Reiterated

06/13/25

UBS reiterates Buy Rating on Nurix (NRIX)UBS analyst David Dai reiterated a Buy rating and $30.00 price target on Nurix (NASDAQ: NRIX).

Peter LawsonBarclays

Barclays

$31

Buy

166.32%

Upside

Reiterated

06/13/25

Barclays Remains a Buy on Nurix Therapeutics (NRIX)

Derek ArchilaWells Fargo

Wells Fargo

$25

Buy

114.78%

Upside

Reiterated

06/12/25

Analysts' Top Healthcare Picks: Nurix Therapeutics (NRIX), Disc Medicine (IRON)

Brian AbrahamsRBC Capital

RBC Capital

$28

Buy

140.55%

Upside

Reiterated

06/12/25

RBC Capital Sticks to Its Buy Rating for Nurix Therapeutics (NRIX)

Gil BlumNeedham

Needham

$27

Buy

131.96%

Upside

Reiterated

06/12/25

Analysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NASDAQ: NRIX) and Telix Pharmaceuticals (Other OTC: TLPPF)

Stephen WilleyStifel Nicolaus

Stifel Nicolaus

$36→$35

Buy

200.69%

Upside

Reiterated

06/02/25

Optimistic Outlook on Nurix Therapeutics: Strategic Partnerships and Financial Gains Drive Buy Rating

Biren AminPiper Sandler

Piper Sandler

$35

Buy

200.69%

Upside

Reiterated

05/07/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Terence FlynnMorgan Stanley

Morgan Stanley

$17

Hold

46.05%

Upside

Reiterated

04/10/25

Cautious Outlook on Nurix Therapeutics Amid Promising Pipeline and Development Uncertainties

Christopher LiuLucid Capital

Lucid Capital

$35→$36

Buy

209.28%

Upside

Reiterated

04/09/25

Sudan LoganathanStephens

Stephens

$31→$30

Buy

157.73%

Upside

Reiterated

04/09/25

Nurix (NRIX) PT Lowered to $30 at StephensStephens analyst Sudan Loganathan lowered the price target on Nurix (NASDAQ: NRIX) to $30.00 (from $31.00) while maintaining a Overweight rating.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Nurix Therapeutics

1 Month

xxx

Success Rate

7/11 ratings generated profit

Average Return

+6.98%

reiterated a xxx

rating 18 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 63.64% of your transactions generating a profit, with an average return of +6.98% per trade.

3 Months

xxx

Success Rate

8/11 ratings generated profit

Average Return

+30.82%

reiterated a xxx

rating 18 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 72.73% of your transactions generating a profit, with an average return of +30.82% per trade.

1 Year

Derek ArchilaWells Fargo

Success Rate

6/11 ratings generated profit

Average Return

+64.42%

reiterated a buy rating 18 days ago

Copying Derek Archila's trades and holding each position for 1 Year would result in 54.55% of your transactions generating a profit, with an average return of +64.42% per trade.

2 Years

xxx

Success Rate

15/19 ratings generated profit

Average Return

+34.17%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 78.95% of your transactions generating a profit, with an average return of +34.17% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NRIX Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NRIX has received 34 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. NRIX average Analyst price target in the past 3 months is 29.50.

Each month's total comprises the sum of three months' worth of ratings.

NRIX Financial Forecast

NRIX Earnings Forecast

Next quarter’s earnings estimate for NRIX is -$0.71 with a range of -$0.96 to -$0.49. The previous quarter’s EPS was -$0.67. NRIX beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.16% of the time in the same period. In the last calendar year NRIX has Preformed in-line its overall industry.

NRIX Sales Forecast

Next quarter’s sales forecast for NRIX is $16.90M with a range of $0.00 to $33.60M. The previous quarter’s sales results were $18.45M. NRIX beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.46% of the time in the same period. In the last calendar year NRIX has Preformed in-line its overall industry.

NRIX Stock Forecast FAQ

What is NRIX’s average 12-month price target, according to analysts?

Based on analyst ratings, Nurix Therapeutics, Inc.’s 12-month average price target is 29.50.

What is NRIX’s upside potential, based on the analysts’ average price target?

Nurix Therapeutics, Inc. has 153.44% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is NRIX a Buy, Sell or Hold?

Nurix Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 13 buy ratings, 2 hold ratings and 0 sell ratings.

What is Nurix Therapeutics, Inc.’s price target?

The average price target for Nurix Therapeutics, Inc. is 29.50. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $36.00 ,the lowest forecast is $16.00. The average price target represents 153.44% Increase from the current price of $11.64.

What do analysts say about Nurix Therapeutics, Inc.?

Nurix Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.

How can I buy shares of NRIX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Nurix Therapeutics (NRIX) Stock Forecast & Price Target

NRIX Analyst Ratings

NRIX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Nurix Therapeutics

NRIX Analyst Recommendation Trends

NRIX Financial Forecast

NRIX Earnings Forecast

NRIX Sales Forecast

NRIX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts